Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Buy" by Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has earned an average recommendation of "Buy" from the five ratings firms that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $41.20.

A number of brokerages have recently issued reports on ELVN. HC Wainwright boosted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Robert W. Baird boosted their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They issued a "buy" rating and a $37.00 price target on the stock. Finally, Jones Trading dropped their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $18.74 on Tuesday. The company has a market capitalization of $919.57 million, a P/E ratio of -9.76 and a beta of 0.93. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $30.03. The company's 50 day moving average price is $20.68 and its 200-day moving average price is $20.09.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Activity at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 12,500 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $21.40, for a total transaction of $267,500.00. Following the transaction, the insider owned 965,188 shares in the company, valued at $20,655,023.20. The trade was a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total transaction of $277,250.00. Following the transaction, the chief executive officer owned 952,892 shares in the company, valued at approximately $21,135,144.56. The trade was a 1.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,751 shares of company stock worth $2,169,325 in the last quarter. Company insiders own 25.90% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ELVN. KLP Kapitalforvaltning AS acquired a new position in Enliven Therapeutics during the fourth quarter worth $97,000. Vanguard Group Inc. raised its holdings in Enliven Therapeutics by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after buying an additional 55,283 shares during the last quarter. Wellington Management Group LLP raised its holdings in Enliven Therapeutics by 15.3% during the fourth quarter. Wellington Management Group LLP now owns 80,916 shares of the company's stock worth $1,821,000 after buying an additional 10,746 shares during the last quarter. Geode Capital Management LLC raised its holdings in Enliven Therapeutics by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 762,718 shares of the company's stock worth $17,165,000 after buying an additional 12,510 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics during the fourth quarter valued at approximately $200,000. Institutional investors and hedge funds own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.